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Abstract: A recent meta-analysis of selected randomized clinical trials (RCTs), in which 
population  groups  of  differing  ages  and  health  status  were  supplemented  with  various 
doses of -carotene, vitamin A, and/or vitamin E, found that these interventions increased 
all-cause  mortality.  However,  this  meta-analysis  did  not  consider  the  rationale  of  the 
constituent RCTs for antioxidant supplementation, none of which included mortality as a 
primary outcome. As the rationale for these trials was to test the hypothesis of a potential 
benefit of antioxidant supplementation, an alternative approach to a systematic evaluation 
of these RCTs would be to evaluate this outcome relative to the putative risk of greater 
total  mortality.  Thus,  we  examined  these  data  based  on  the  primary  outcome  of  the 
66 RCTs  included  in  the  meta-analysis  via  a  decision  analysis  to  identify  whether  the 
results  provided  a  positive  (i.e.,  benefit),  null  or  negative  (i.e.,  harm)  outcome.  Our 
evaluation indicated that of these RCTs, 24 had a positive outcome, 39 had a null outcome, 
and 3 had a negative outcome. We further categorized these interventions as primary (risk 
reduction  in  healthy  populations)  or  secondary  (slowing  pathogenesis  or  preventing 
recurrent events and/or cause-specific mortality) prevention or therapeutic (treatment to 
improve  quality  of  life,  limit  complications,  and/or  provide  rehabilitation)  studies,  and 
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determined positive outcomes in 8 of 20 primary prevention studies, 10 of 34 secondary 
prevention studies, and 6 out of 16 therapeutic studies. Seven of the eight RCTs with a 
positive  outcome  in  primary  prevention  included  participants  in  a  population  where 
malnutrition is frequently described. These results suggest that analyses of potential risks 
from antioxidant supplementation should be placed in the context of a benefit/risk ratio. 
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1. Introduction 
Several research approaches, particularly observational studies, suggest that diets rich in antioxidant 
nutrients, particularly vitamins C and E, -carotene, and selenium, and/or supplements containing one 
or more of these nutrients are associated with a reduction in the risk of several age-related chronic 
diseases,  including  some  forms  of  cancer,  cardiovascular,  eye,  and  neurodegenerative  diseases,  
e.g., references [1-7]. These relatively consistent results stimulated the initiation of several large scale, 
randomized  clinical  trials  (RCTs),  including  the  Nutrition  Intervention  Trials  (NIT)[8];  
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study [9]; Gruppo Italiano per lo Studio 
della Sopravvivenza nell’Infarto miocardico-Prevenzione trial [10]; Heart Outcomes Prevention Study 
(HOPE) and Heart Outcomes Prevention Evaluation-The Ongoing Outcomes (HOPE-TOO)[11,12]; 
Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) study [13]; Women’s Health 
Study (WHS)[14]; Physicians’ Health Study (PHS) and Physicians’ Health Study II (PHS-II)[15,16]; 
Age-Related Eye Disease Study (AREDS)[17,18]; and Selenium and Vitamin E Cancer Prevention 
Trial (SELECT)[19]. The overall results of most of these RCTs have been presented as equivocal 
or null. 
These RCTs were mostly designed to test the efficacy of antioxidant supplementation in the primary 
or secondary prevention of cancer and/or cardiovascular disease. Due largely to issues of cost and 
statistical power, most of these RCTs have tested only one or two antioxidant nutrients and, thus, may 
not have fully benefited from the dynamic interrelationships between these nutrient and other dietary 
and endogenous components of the antioxidant defense network. Importantly, none of these studies 
employed  inclusion  criteria  such  as  low  antioxidant  nutrient  intake  or  status  and/or  elevated 
biomarkers of oxidative stress, or determined outcome measures as to whether these parameters were 
affected by the intervention, elements necessary to testing the hypothesis that the putative benefit 
derived from these nutrients is due to their antioxidant actions [20,21].  
The  limitations  of  RCTs  in  testing  the  efficacy  and  safety  of  nutrients  are  not  often  fully 
appreciated. The RCT research approach was developed for drugs, where interventions are designed to 
cure a disease, not produced by their absence; nutrients prevent dysfunction that would result from 
their inadequate intake. Further, drug effects are generally intended to be acute, large, and with a 
specific target for action, while nutrient effects are typically chronic, modest, and polyvalent in scope. 
In addition, drug effects can be tested against a non-exposed (placebo) contrast group, whereas it is 
impossible and/or unethical to attempt a zero intake group for nutrients [22]. Nonetheless, RCTs are Nutrients 2010, 2  
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currently considered the ―gold standard‖ for evaluating dietary interventions and, thus, receive the 
attention of most meta-analyses on this topic.  
In  addition  to  using  RCTs  to  test  the  potential  health  benefits  of  antioxidant  supplements,  
meta-analyses may also provide an approach to determining their safety. Although specific adverse 
events have been reported for most nutrients, as reflected in established Tolerable Upper Intake Levels 
[23], all-cause or total mortality has sometimes utilized as a global indicator of safety in meta-analyses 
of RCTs [24-26]. In their meta-analysis, Bjelakovic et al. [27,28] concluded that vitamins A and E and  
-carotene were associated with an increased risk of all-cause mortality with a relative risk (95% 
confidence interval) of 1.16 (1.10–1.24), 1.04 (1.01–1.07), and 1.07 (1.02–1.11), respectively. This 
report was based on 66 RCTs utilizing >1000 participants and excluded any study absent a report of 
mortality (747 articles) or considered by the authors to be of low methodologic quality (21 articles). 
The results from the RCTs selected by Bjelakovic et al. [27] may not be readily extrapolated to all 
other studies with low power due to too few subjects. Thus, we have selected a power-independent 
approach to reevaluate this meta-analysis with respect to its primary outcome of total mortality as well 
as examining their impact on the efficacy of the intervention. 
2. Methods 
We focus here on the primary endpoints of these RCTs. These data were extracted from all but two 
of the studies used in the Bjelakovic et al. [27] meta-analysis. The report by Chandra [29] (reference 
no. 39) has been excluded because of documented deficiencies in the integrity of data [30]. The article 
by Bonelli [31] (reference no. 57) has been excluded because a copy of this publication could not be 
obtained.  The  remaining  66  studies  were  reviewed  and  classified  into  three  groups  with  separate 
analyses  conducted  for  studies  with  primary  prevention,  secondary  prevention,  and  therapeutic 
efficacy as their primary goal. Studies of primary prevention are defined as interventions in generally 
healthy people intended to reduce the risk of a disease or disability. Secondary prevention actions 
described here involve dietary interventions (nutrient supplementation) in a diagnosed group to slow 
the pathogenesis of the disease and/or prevent recurrent events or cause-specific mortality. Studies of 
therapeutic  efficacy  are  directed  to  improving  the  quality  of  life,  limiting  complications,  and/or 
providing rehabilitation to a patient group. Importantly, the therapeutic efficacy of dietary supplements 
is  always  tested  concurrently  with  established  standards  of  care,  often  including  polypharmacy 
regimens, as withdrawing these other treatments would be unethical. 
All the studies were independently classified by the authors and rated with regard to the primary 
study goal as: positive or goal achieved (+1), null outcome (0) or adverse effect (−1). Differences in 
classification  or  rating  between  the  authors  were  documented  and  discussions  held  to  resolve  the 
conflicts until unanimous agreement was reached. The percentage of studies with positive results in the 
three groups of studies was compared using a χ




Efficacy of Antioxidant Interventions 
Study  outcomes were  listed with regard  to  their design as primary or secondary prevention or 
therapy. When studies were reported to have more than one study outcome both were listed. Overall, 
24  of  66  RCTs  (36%)  reported  a  positive  outcome  of  the  intervention  indicating  a  benefit  of 
antioxidant supplementation. Studies testing the effect of primary prevention by antioxidants showed 
positive outcomes in 8 of 21 studies (38%) while a single study reported a negative outcome. Reports 
from  secondary  prevention  RCTs  showed  positive  outcomes  in  10  of  29  studies  (34%)  while 
2 obtained  negative  outcomes.  In  studies  directed  to  therapeutic  outcomes,  6  of  16  RCTs  (38%) 
achieved positive results. No significant difference (p = 0.78) was observed in secondary prevention 
trials regarding outcome compared with other studies. Most of these RCTs (60%) found neither benefit 
nor harm from the antioxidant supplement related to their primary goal (Tables 1 and 2). 
Table 1. Study outcome (intervention effects of antioxidant trials) with respect to primary 
goal and study type. 
Group of Studies  Outcome  Number  Percent (%) 
All studies (66 RCTs) 
+1  24  36 
0  39  60 
−1  3  4 
Primary prevention studies (20 RCTs) 
+1  8  38 
0  12  57 
−1  1  5 
Secondary prevention studies (34 RCTs) 
+1  10  34 
0  17  59 
−1  2  7 
Therapeutic intervention studies (16 RCTs) 
+1  6  37.5 
0  10  62.5 
−1  0  0 
Seven of the eight RCTs with a positive outcome in primary prevention included participants in a 
population where malnutrition is frequently described [8,13,33-37]. For example, five of these studies 
were conducted in the elderly, a population often described as at risk of micronutrient deficiencies [33-37]. 
The positive outcome in the SU.VI.MAX study of Hercberg et al. [13] was obtained only in males 
who, compared to the female participants, presented with a lower baseline status of antioxidants during 
enrolment  into  the  study.  The  participants  in  the  Nutrition  Intervention  Trials  were  residents  of 
Linxian, China, an area with a high prevalence of malnutrition [8]. 
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Table 2. Studies of Bjelakovic et al. [27] and their outcome with respect to the study type. 
Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






35  Gillilan et al. [38] 
Quantitative evaluation of vitamin E in the treatment of 
angina pectoris 
  x        x 
36  McKeown-Eyssen et al. [39] 
A randomized trial of vitamins C and E in the 
prevention of recurrence of colorectal polyps 
x        x   
37  Greenberg et al. [40] 
A clinical trial of beta carotene to prevent basal-cell 
and squamous-cell cancers of the skin. The Skin 
Cancer Prevention Study Group 
  x      x   
38  Penn et al. [36] 
The effect of dietary supplementation with vitamins A, 
C and E on cell-mediated immune function in elderly 
long-stay patients: A randomized controlled trial 
x      x     
40  Murphy et al. [41] 
Impact of vitamin A supplementation on the incidence 
of infection in elderly nursing-home residents: A 
randomized controlled trial 
  x    x     
41  Blot et al. [8] 
Nutrition intervention trials in Linxian, China: 
Supplementation with specific vitamin/mineral 
combinations, cancer incidence, and disease-specific 
mortality in the general population 
x      x     
42  Li et al. [42] 
Nutrition intervention trials in Linxian, China: Multiple 
vitamin/mineral supplementation, cancer incidence, and 
disease-specific mortality among adults with 
esophageal dysplasia 
  x      x   
43  Wenzel et al. [43] 
Alcohol-induced toxic hepatitis-a "free radical" 
associated disease. Lowering fatality by adjuvant 
antioxidant therapy 
x          x Nutrients 2010, 2  
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Table 2. Cont. 
Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






44  Greenberg et al. [44]  A clinical trial of antioxidant vitamins to prevent colorectal 
adenoma. Polyp Prevention Study Group 
  x      x   
45  Pike and Chandra [37]  Effect of vitamin and trace element supplementation on immune 
indices in healthy elderly 
x      x     
46  Takamatsu et al. [45]  Effects on health of dietary supplementation with 100 mg  
d-alpha-tocopheryl acetate, daily for 6 years 
x      x     
47  de la Maza et al. [46]  Effects of long-term vitamin E supplementation in  
alcoholic cirrhotics 
  x        x 
48  ter Riet et al. [47]  Randomized clinical trial of ascorbic acid in the treatment of 
pressure ulcers 
  x        x 
49  Clark et al. [48]  Effects of selenium supplementation for cancer prevention in 
patients with carcinoma of the skin: A randomized controlled trial 
x        x   
50  Hennekens et al. [15]  Lack of the effect of long-term supplementation with beta carotene 
on the incidence of malignant neoplasms and cardiovascular disease 
  x    x     
51  Hogarth et al. [49]  Nutritional supplementation in elderly medical in-patients: A 
double-blind placebo-controlled trial 
  x      x   
52  Richer [50]  Multicenter ophthalmic and nutritional age-related macular 
degeneration study, II: Antioxidant intervention and conclusions 
x          x 
53  Stephens et al. [51]  Randomised controlled trial of vitamin E in patients with coronary 
disease: Cambridge Heart Antioxidant Study (CHAOS) 
x          x 
54  Girodon et al. [33]  Effect of micronutrient supplementation on infection in 
institutionalized elderly subjects: A controlled trial 
x      x     
55  Moon et al. [52]  Effect of retinol in preventing squamous cell skin cancer in 
moderate-risk subjects: A randomized, double-blind, controlled trial 
x        x   Nutrients 2010, 2  
 
935 
Table 2. Cont. 
Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






56  Sano et al. [53]  A controlled trial of selegiline, alpha-tocopherol, or both as 
treatment for Alzheimer`s disease: The Alzheimer`s Disease 
Cooperative Study 
x          X 
58  GISSI [10]  Dietary supplementation with N-3 polyunsaturated fatty acids 
and vitamin E after myocardial infarction: Results of the 
GISSI-Prevenzione trial 
  x      x   
59  Girodon et al. [34]  Impact of trace elements and vitamin supplementation on 
immunity and infections in institutionalized elderly patients: 
A randomized controlled trial 
x      x     
60  Green et al. [54]  Daily sunscreen application and beta-carotene 
supplementation in prevention of basal-cell and squamous-
cell carcinomas of the skin: A randomised controlled trial 
  x    x     
61  Boaz et al. [55]  Secondary prevention with antioxidants of cardiovascular 
disease in endstage renal disease (SPACE): Randomised 
placebo-controlled trial 
x        x   
62  Correa et al. [56]  Chemoprevention of gastric dysplasia: Randomized trial of 
antioxidant supplements and anti-helicobacter pylori therapy 
x        x   
63  Jacobson et al. [57]  Effects of a 6-month vitamin intervention on DNA damage in 
heavy smokers 
  x    x     
64  Age-Related Eye Disease 
Study research Group [18] 
A randomized, placebo-controlled, clinical trail of high-dose 
supplementation with vitamins C and E and beta carotene for 
age-related cataract and vision loss 
  x      x   
65  Brown et al. [58]  Simvastatin and niacin, antioxidant vitamins, or the 
combination for the prevention of coronary disease 
  x      x   Nutrients 2010, 2  
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Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






66  Desnuelle et al. [59]  A double-blind, placebo-controlled randomized clinical trail 
of alpha-tocopherol (vitamin E) in the treatment of 
amyotrophic lateral sclerosis 
x          x 
67  Stevic et al. [60]  A controlled trial of combination of methionine and 
antioxidants in ALS patients 
x          x 
68  You et al. [61]  An intervention trial to inhibit the progression of 
precancerous gastric lesions: Compliance, serum 
micronutrients and S-allyl cysteine levels, and toxicity 
  x      x   
69  de Gaetano and Collaborative 
Group of the Primary 
Prevention Project [62] 
Low-dose aspirin and vitamin E in people at cardiovascular 
risk: A randomised trial in general practice 
  x      x   
70  de Waart et al. [63]  Effect of glutathione S-transferase M 1 genotype on 
progression of atherosclerosis in lifelong male smokers 
  x      x   
71  Chylack et al. [64]  The Roche European American Cataract Trial (REACT): A 
randomized clinical trial to investigate the efficacy of an 
oral antioxidant micronutrient mixture to slow progression 
of age-related cataract 
x        x   
72  Graat et al. [65]  Effect of daily vitamin E and multivitamin-mineral 
supplementation on acute respiratory tract infections in 
elderly persons: A randomized controlled trial 
    x  x     
73  Heart Protection Study 
Collaborative Group [66] 
MRC/BHF Heart Protection Study of antioxidant vitamin 
supplementation in 20536 high-risk individuals: A 
randomised placebo-controlled trial 
  x      x   
74  Hodis et al. [67]  Alpha-tocopherol supplementation in healthy individuals 
reduces low-density lipoprotein oxidation but  
not atherosclerosis 
  x    x     Nutrients 2010, 2  
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Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






75  Waters et al. [68]  Effects of hormone replacement therapy and antioxidant vitamin 
supplements on coronary atherosclerosis in postmenopausal women: 
A randomized controlled trial 
    x    x   
76  White et al. [69]  Dietary antioxidants and DNA damage in patients on long-term acid 
suppression therapy. a randomized controlled study 
  x      x   
77  Wluka et al. [70]  Supplementary vitamin E does not affect the loss of cartilage volume 
in knee osteoarthritis: A randomized placebo controlled study 
  x        x 
78  Collins et al. [71]  PoleStriding exercise and vitamin E for management of peripheral 
vascular disease 
  x        X 
79  Prince et al. [72]  Oral antioxidant supplementation for fatigue associated with primary 
biliary cirrhosis: Results of a multicentre, randomized,  
placebo-controlled, cross-over trial 
  x        x 
80  Salonen et al. [73]  Antioxidant supplementation in atherosclerosis prevention study:  
Six-year effect of combined vitamin C and E supplementation on 
atherosclerotic progression: The Antioxidant Supplementation in 
Atherosclerosis Prevention (ASAP) Study 
x        x   
81  Sasazuki et al. [74]  The effect of 5-year vitamin C supplementation on serum pepsinogen 
level and Helicobacter pylori infection 
x        x   
82  Takagi et al. [75]  Pilot clinical trial of the use of alpha-tocopherol for the prevention of 
hepatocellular carcinoma in patients with liver cirrhosis 
  x      x   
83  Virtamo et al. [9]  Incidence of cancer and mortality following alpha-tocopherol and 
beta-carotene supplementation: A postintervention follow-up 
  x    x     
84  Allsup et al. [76]  Can a short period of micronutrient supplementation in older 
institutionalized people improve response to influenza vaccine? 
  x    x     Nutrients 2010, 2  
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Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






85  Goodman et al. [77]  The Beta-Carotene and Retinol Efficacy Trial: Incidence of 
lung cancer and cardiovascular disease mortality during 6-year 
follow-up after stopping beta-carotene and retinol supplements 
  x    x     
86  Hercberg et al. [13]  The SU.VI.MAX Study: A randomized, placebo-controlled 
trial of the health effects of antioxidant vitamins and minerals 
x      x     
87  Manuel-y-Keenoy et al. [78]  Impact of vitamin E supplementation on lipoprotein 
peroxidation and composition in type 1 diabetic patients treated 
with atorvastatin 
  x      x   
88  McNeil et al. [79]  Vitamin E supplementation and cataract: Randomized 
controlled trial 
  x      x   
89  Meydani et al. [35]  Vitamin E and respiratory tract infections in elderly nursing 
home residents: A randomized controlled trial 
x      x     
90  Mezey et al. [80]  A randomized placebo controlled trial of vitamin E for 
alcoholic hepatitis 
  x        x 
91  Richer [81]  Double-masked, placebo-controlled, randomized trial of lutein 
and antioxidant supplementation in the intervention of atrophic 
age-related macular degeneration: The Veterans LAST study 
(Lutein Antioxidant Supplementation Trial) 
x        x   
92  Avenell et al. [82]  Effect of multivitamin and multimineral supplements on 
morbidity from infections in older people (MAVIS trial): 
Pragmatic, randomised, double blind, placebo controlled trial 
  x    x     
93  Graf et al. [83]  High dose vitamin E therapy in amyotrophic lateral sclerosis as 
add-on therapy to riluzole: Results of a placebo-controlled 
double-blind study 
  x        x Nutrients 2010, 2  
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Ref. No. *  Author(s) [Ref. No.]  Publication Title 
Outcome  Type of Study 






94  Lee et al. [14]  Vitamin E in the primary prevention of cardiovascular disease and 
cancer: The Women`s Health Study: A randomized controlled trial 
  x    x     
95  Limburg et al. [84]  Randomized, placebo-controlled, esophageal squamous cell cancer 
chemoprevention trial of selenomethionine and celecoxib 
  x      x   
96  Lonn et al. [12]  Effects of long-term vitamin E supplementation on cardiovascular 
events and cancer: A randomized controlled trial 
    x    x   
97  Marras et al. [85]  Parkinson Study Group. Survival in Parkinson disease:  
Thirteen-year follow-up of the DATATOP cohort 
  x        x 
98  Mooney et al. [86]  Antioxidant vitamin supplementation reduces benzo(a)pyrene-DNA 
adducts and potential cancer risk in female smokers 
  x    x     
99  Petersen et al. [87]  Vitamin E and donepezil for the treatment of mild  
cognitive impairment 
  x        x 
100  Tam et al. [88]  Effects of vitamin C and E on oxidative stress markers and 
endothelial function in patients with systemic lupus erythematosus: 
A double blind, placebo controlled pilot study 
  x      x   
101  Witte et al. [89]  The effect of micronutrient supplementation on quality-of-life and 
left ventricular function in elderly patients with chronic 
heart failure 
x        x   
102  Rayman et al. [90]  Impact of selenium on mood and quality of life: A randomized, 
controlled trial 
  x    x     
* The numbering of the references is consistent with those reported in Bjelakovic et al. [27]. 




Assessing  the  primary  goal  (i.e.,  the  determination  of  benefit)  of  the  RCTs  analyzed  by  
Bjelakovic et al. [27] places their conclusion about the risk of mortality in a context relevant to the 
consideration  of  using  antioxidant  supplements  in  health  promotion  and  therapeutic  treatments. 
Clearly, increases in disease-specific or all-cause mortality are never objectives of intervention studies 
but, when observed, are a reason to stop the protocol early. Nonetheless, it is worth noting that the risk 
of mortality in any RCTs of nutrients will be substantially dependent upon the nature of the cohort, 
including parameters such as advanced age, severe disease status, toxicity of drug treatments, etc. 
Importantly, in our analysis, we did not evaluate as positive, null or adverse the outcomes of the 
405 studies  excluded  from  the  Bjelakovic  et  al.  [27]  study  because  no  death  occurred.  This  is  a 
limitation to our study as it does not provide a full assessment of the potential benefits versus the risk 
of total mortality from antioxidant supplementation. 
With  regard  to  the  efficacy  of  antioxidant  supplementation  in  the  RCTs  included  in  the  
meta-analysis by Bjelakovic et al. [27], we find that the benefit of the intervention was statistically 
significant  principally  in  those  populations  generally  characterized  at  risk  for  micronutrient 
deficiencies,  including  those  of  vitamins  C  and  E,  selenium,  and  beta-carotene  as  well  as  other 
nutrients such as zinc that contribute to the antioxidant defense network. This relationship may suggest 
that dietary supplementation for the prevention or treatment of chronic diseases is likely to be most 
effective in those with inadequate intakes, though absent overt deficiency syndromes. Further, this 
relationship  also  suggests  there  is  a  threshold  nutrient  status  above  which  additional  intake  via 
supplementation might provide no further benefit. However, the threshold for adequate intake of any 
nutrient is recognized as dependent on an individual’s specific requirements as affected by parameters 
such as age, sex, health status, and nutrigenomic factors such as polymorphisms. The contribution of 
polymorphisms  to  antioxidant  defenses  can  be  illustrated  by  the  manganese-dependent  superoxide 
dismutase polymorphism associated with a lower risk of prostate cancer in the presence of high intakes 
of selenium to optimize glutathione peroxidase activity [91]. 
Critical  to  the  validity  of  a  meta-analysis  is  the  statistical  accounting  for  study  variability, 
particularly  when  information  from  multiple  RCTs  is  combined,  including  the  requirement  for 
considering model uncertainty and trial effect. For example, Berry et al. [92] employed a Bayesian 
hierarchical meta-analytic method rather than the frequentist approach to synthesize results from the 
RCTs of vitamin E supplementation used by Bjelakovic et al. [27] and Miller et al. [26] and concluded 
that  vitamin  E  intake  is  unlikely  to  affect  mortality  regardless  of  dose.  Other  criticisms  of  the 
Bjelakovic et al. [27] meta-analysis have been noted, such as including small RCTs with few deaths; 
attributing deaths occurring after only a few months of antioxidant treatment; combining different 
nutrients in different forms with a large range of doses in a wide variety of population groups with 
varying  health  status;  misclassifying  some  studies  as  being  of  high  risk  of  bias;  and  basing  the 
conclusion about antioxidant-specific effects on models that excluded selenium trials. However, no 
study before has considered evaluating the same studies selected by Bjelakovic et al. [27] for their benefits.  
Our approach to considering overall beneficial outcomes of the RCTs selected by Bjelakovic et al. [27] 
provides a balancing perspective to their meta-analysis focused exclusively on the risk of all-cause 
mortality. It is worthwhile noting limitations associated with the use of meta-analyses of total mortality Nutrients 2010, 2  
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as  an  indication  of  harm  without  determining  the  cause  of  death.  Bjelakovic  et  al.  [26]  did  not 
investigate  cause-specific  mortality  and  thus  could  not  eliminate  those  that  lack  any  biological 
plausibility to antioxidant (or pro-oxidant) toxicity such as accidental deaths and homicides.  
It should be noted that we did not include in our evaluation benefits found only in subgroups from 
the RCTs selected by Bjelakovic et al. [27]. For examples, we judged the WHS to have an overall null 
outcome among its 39,876 women >45 years of age receiving a 600 IU vitamin E supplement every 
other day for 10 years despite the observation by Lee et al. [14] of a significant reduction in the 
relative risk (RR) of the primary outcome of myocardial infarction, cardiovascular death or stroke 
among women >65 years of age (RR = 0.74; 95% Confidence Interval [CI]: 0.59–0.93; P = 0.009). 
Similarly, we judged the Vitamin E Atherosclerosis Study (VEAPS) to have a null effect (P = 0.08) on 
its primary trial endpoint of the rate of change in right distal common carotid artery intima-media 
thickness in 332 healthy men and women ≥40 years receiving 400 IU vitamin E for three years despite 
the observation by Hodis et al. [67] of significantly reduced concentrations of circulating oxidized low 
density  lipoprotein  (LDL)  and  increased  resistance  of  LDL  to  oxidation,  both  biomarkers  of 
cardiovascular disease risk. While such subgroup analyses typically lack the statistical power from 
which to draw definitive conclusions, these results do suggest that further RCTs are warranted to test 
the potential benefit of the intervention in that population.  
As the relative number of positive outcomes evaluated in our analysis was based only on those 
studies analyzed by Bjelakovic et al. [27], it is possible we have underestimated the proportion of 
studies demonstrating benefit. For example, Bjelakovic et al. [27] selected the mortality data only from 
the AREDS study [18] report examining the effect of a combination antioxidant supplement on the 
development of cataracts and vision loss which had a null outcome (Table 2). However, the same 
mortality  data,  albeit  provided  in  more  detail,  is  available  from  the  AREDS  study  [17]  report 
examining the effect of the same supplement on age-related macular degeneration and vision loss in 
which  a  significant  positive  outcome  was  achieved.  Further,  in  evaluating  the  positive,  null  and 
adverse outcomes of this set of studies, we did not take advantage of follow-up reports published after 
publication of the Bjelakovic et al. [27] article. For example, Watters et al. [93] recently examined 
prospectively the serum antioxidant status in men diagnosed with prostate cancer during the ATBC 
Study of 29,133 Finish smokers and in their 20 years follow-up found improved survival among the 
men with higher serum -tocopherol at baseline (Hazard Ratio [HR] = 0.67; 95% CI: 0.45–1.00;  
P = 0.03), especially among cases who had received the vitamin E supplement and who were in the 
highest quintile of -tocopherol at baseline (HR = 0.51; 95% CI: 0.20–0.90; P = 0.04) and at the  
3-year follow-up measurement (HR = 0.26; 95% CI, 0.09–0.71; P = 0.02). Thus, a review including 
follow-up  of  earlier  RCTs  and  new  RCTs,  e.g.,  of  the  SELECT  [19]  would  offer  a  more 
comprehensive consideration of the benefit in relation to a potential (mortality) risk of antioxidant 
supplementation than provided here. 
As noted above, the outcome of human studies on dietary antioxidants will depend on the initial 
status  of  the  antioxidant  defense  network  and  oxidative  stress  in  each  subject,  the  dose(s)  of  the 
nutrient(s), and the concentration threshold for action of each nutrient. One of the major challenges in 
conducting  RCTs  to  test  the  efficacy  and  safety  of  antioxidants  (and  other  nutrients)  as  dietary 
supplements in reducing the risk of chronic disease, especially in primary prevention, is the need for 
very  long  durations  of  the  intervention  as  we  lack  validated  intermediary  biomarkers  of  these Nutrients 2010, 2  
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conditions. The RCT conducted by Milman et al. [94] demonstrating the reduction of cardiovascular 
events (myocardial infarct, cardiovascular death, and stroke) by 400 IU/d vitamin E in type 2 diabetics 
with  a  haptoglobin  2-2  genotype  but  not  other  alleles  suggests  as  well  the  need  to  consider 
nutrient/gene  interactions  in  the  study  design.  Total  deaths  within  a  single  study  or  as  part  of  a  
meta-analysis may be a utilized as one measure of the toxicity of a chronic intervention; however, 
collection of specific mortality data is essential as RCTs of dietary supplements cannot otherwise 
establish either biological plausibility or causality due to the inability to determine the response to 
discontinuation and the response to rechallenge. 
The operational definition of dietary antioxidants provided by the U.S. Institute of Medicine states 
that  these  nutrients  significantly  decrease  the adverse  effects  of  reactive  species,  such  as  reactive 
oxygen and nitrogen species, on normal physiological function in humans [95]. These adverse effects 
are  essentially  described  as  oxidatively  modified  products  of  DNA,  lipids,  and  protein  such  as  
8-hydroxy-2’-deoxyguanosine,  F2-isoprostanes,  and  protein  carbonyls,  respectively.  However,  the 
efficacy of different antioxidants in achieving this effect is critically dependent on a variety of factors, 
including  the  baseline  value  of  these  biomarkers  and  the  dose  and  duration  of  treatment.  While 
lowering these biomarkers has been associated in many experimental and observational studies with a 
reduced risk of some age-related pathologies and chronic diseases, no evidence appears available to 
suggest they are correlated with premature mortality. Importantly, the classification of vitamins C and E, 
carotenoids, flavonoids and related polyphenols as dietary antioxidants fails suggest their other various 
mechanisms of action, including anti-inflammation, induction of phase 2 detoxification enzymes, and 
modulation  of  redox  sensitive  signal  transduction  and  gene  expression.  Thus,  new  studies  of  the 
clinical efficacy and safety of antioxidants as dietary supplements must consider appropriate forms and 
doses of the ingredients, a duration relevant to the pathogenesis and/or progression of the disease, and 
the biologically relevant molecular targets in populations most likely to respond in a fashion providing 
a high benefit/risk ratio.  
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